ATE409227T1 - Verfahren und zusammensetzungen zum screening unter verwendung des diphtheria-toxins - Google Patents

Verfahren und zusammensetzungen zum screening unter verwendung des diphtheria-toxins

Info

Publication number
ATE409227T1
ATE409227T1 AT00993043T AT00993043T ATE409227T1 AT E409227 T1 ATE409227 T1 AT E409227T1 AT 00993043 T AT00993043 T AT 00993043T AT 00993043 T AT00993043 T AT 00993043T AT E409227 T1 ATE409227 T1 AT E409227T1
Authority
AT
Austria
Prior art keywords
screening
methods
diphtheria toxin
compositions
modulators
Prior art date
Application number
AT00993043T
Other languages
English (en)
Inventor
Todd Kinsella
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE409227T1 publication Critical patent/ATE409227T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00993043T 1999-11-12 2000-11-13 Verfahren und zusammensetzungen zum screening unter verwendung des diphtheria-toxins ATE409227T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16518999P 1999-11-12 1999-11-12

Publications (1)

Publication Number Publication Date
ATE409227T1 true ATE409227T1 (de) 2008-10-15

Family

ID=22597844

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00993043T ATE409227T1 (de) 1999-11-12 2000-11-13 Verfahren und zusammensetzungen zum screening unter verwendung des diphtheria-toxins

Country Status (8)

Country Link
EP (1) EP1261705B1 (de)
JP (1) JP2003513670A (de)
AT (1) ATE409227T1 (de)
AU (1) AU2904401A (de)
CA (1) CA2396626A1 (de)
DE (1) DE60040348D1 (de)
DK (1) DK1261705T3 (de)
WO (1) WO2001034806A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060433B1 (en) * 1999-11-12 2006-06-13 Rigel Pharmaceuticals, Inc. Methods and compositions for screening using diphtheria toxin constructs
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
DK1228233T3 (da) * 1999-11-10 2007-05-14 Rigel Pharmaceuticals Inc Fremgangsmåder og sammensætninger omfattende grönfluorescerende proteiner (GFP) fra Renilla
US20030170724A1 (en) 2002-03-08 2003-09-11 Anderson David C. Methods of identifying target polypeptides
WO2003075859A2 (en) * 2002-03-08 2003-09-18 Rigel Pharmaceuticals, Inc. COMPOUNDS THAT MODULATE PROCESSES ASSOCIATED WITH IgE PRODUCTION AND METHODS AND KITS FOR IDENTIFYING AND USING THE SAME
US7189523B2 (en) 2002-07-16 2007-03-13 Rigel Pharmaceuticals, Inc. Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
KR20090075800A (ko) * 2006-09-20 2009-07-09 재단법인 한국파스퇴르연구소 세포에서의 표적 단백질 후보의 발현을 검출 및/또는 정량하는 방법 및 소형 분자 모듈레이터의 표적 단백질을 동정하는 방법
KR101482187B1 (ko) * 2013-01-14 2015-01-14 (주)넥스젠바이오텍 녹색형광단백질―인간상피세포재생인자 융합단백질의 생산을 위한 유전자 컨스트럭트 및 이를 이용한 녹색형광단백질-인간상피세포재생인자 융합단백질의 생산방법
KR101661912B1 (ko) * 2016-01-29 2016-10-04 (주)넥스젠바이오텍 녹색형광단백질-인간 상피세포재생인자 융합단백질을 유효성분으로 포함하는 주름 개선 및 항노화 화장료 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3724495A (en) * 1994-09-13 1996-03-29 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
US7001733B1 (en) * 1998-05-12 2006-02-21 Rigel Pharmaceuticals, Inc. Methods and compositions for screening for modulations of IgE synthesis, secretion and switch rearrangement

Also Published As

Publication number Publication date
DK1261705T3 (da) 2009-02-02
AU2904401A (en) 2001-06-06
CA2396626A1 (en) 2001-05-17
DE60040348D1 (de) 2008-11-06
JP2003513670A (ja) 2003-04-15
EP1261705A2 (de) 2002-12-04
WO2001034806A9 (en) 2002-07-04
EP1261705B1 (de) 2008-09-24
WO2001034806A2 (en) 2001-05-17
WO2001034806A3 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
NO20061736L (no) Krystallform av epotilon B
ATE466072T1 (de) Bandscheibe
NO20051118L (no) Fremgangsmate til fremstilling av amorfe og keramiske materialer via smeltespinning
BG102950A (en) Antibodies for ed-b domain of fibronectine, their structure and application
DE69725169D1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE338120T2 (de) Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
MX9706069A (es) Nuevos inhibidores de la trombina.
ATE328067T1 (de) Isolierung von mesenchymalen stammzellen und deren verwendung
MXPA01005545A (es) Composicion y metodo para tratamiento de cancer que usan moduladores de transduccion de senales y aceites esenciales vegetales naturales.
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
HK1080467A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
ZA200705177B (en) Lyophilization of virosomes
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
ATE409227T1 (de) Verfahren und zusammensetzungen zum screening unter verwendung des diphtheria-toxins
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
EP1276491A4 (de) Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung
IL196900A0 (en) Autologous t-cell vaccines compositions
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DK1213974T3 (da) Direkte komprimerbart råstof til komprimate
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE60126211D1 (de) Zementklinker, zementzusammensetzung, verfahren zur herstellung von zementklinker und verfahren zur behandlung von alkalihaltigen abfällen
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
DE60135489D1 (de) Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1261705

Country of ref document: EP